Saudi Vigilance Program: Challenges and lessons learned

• Published in: Saudi pharmaceutical journal 2018-03, Vol.26 (3), p.388-395
• Main Authors: Alharf, Adel, Alqahtani, Nasser, Saeed, Ghazi, Alshahrani, Ali, Alshahrani, Mubarak, Aljasser, Nasser, Alquwaizani, Mohammed, Bawazir, Saleh
• Format: Article
• Language: English
• Subjects: Pharmacovigilance; Saudi Food and Drug Authority; Saudi Vigilance Program
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2018.01.002

Pharmacovigilance is vital to public health. Adopting a robust spontaneous reporting system for adverse drug events can counteract most hazards that arise from utilizing medicinal products. Prior to the establishment of the Saudi Food and Drug Authority (SFDA), the number of pharmacovigilance-related activities in Saudi Arabia was limited. In 2009, the SFDA established the National Pharmacovigilance and Drug Safety Center (Saudi Vigilance). The pharmacovigilance system has remarkably improved during the past few years. Several initiatives have been taken to improve the program’s performance. These initiatives include initiation of pharmacovigilance guidelines, enhancement of communication and reporting tools, training sessions for concerned staff and healthcare providers, and compliance from stakeholders. This review article provides an overview of what the Saudi Vigilance program is, focusing on the scope, mission and vision, hierarchy, operational themes, and overall work processes. Additionally, we will shed light on the challenges we encountered during the early phase and on our future plans.